var data={"title":"Magnesium sulfate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Magnesium sulfate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6501?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=magnesium-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Magnesium sulfate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Magnesium sulfate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452590\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epsom Salt [OTC];</li>\n      <li>GoodSense Epsom Salt [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191096\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        Electrolyte Supplement, Parenteral;</li>\n      <li>\n        Magnesium Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191085\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dose represented as magnesium sulfate unless stated otherwise. <b>Note:</b> Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b> 1 g of magnesium sulfate = 98.6 mg elemental magnesium = 8.12 mEq elemental magnesium = magnesium 4.06 mmol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Constipation (occasional):</b> Oral: 2 to 4 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 6 hours. Do not exceed 2 doses per day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Eclampsia/pre-eclampsia (severe): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: IV: An initial total dose of 10 to 14 g administered as follows: 4 g infusion with simultaneous IM injections of 4 to 5 g in each buttock. After the initial IV/IM doses, may administer a 1 to 2 g/hour continuous infusion or may follow with IM doses of 4 to 5 g into alternate buttocks every 4 hours as necessary. Maximum: 40 g/24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing (off-label): IV: 4 to 6 g loading dose followed by 1 to 2 g/hour continuous infusion for at least 24 hours (ACOG 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypomagnesemia, treatment:</b> <b>Note:</b> Treatment depends on severity and clinical status. In asymptomatic patients (when oral route is available), oral replacement therapy is a better replacement method than IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild deficiency: IM: Manufacturer's labeling: 1 g every 6 hours for 4 doses, or as indicated by serum magnesium concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate (serum concentration 1 to 1.5 mg/dL): IV: 1 to 4 g (up to 0.125 g/kg), administer at &le;1 g/hour if asymptomatic; do not exceed 12 g over 12 hours (Kraft, 2005). <b>Note:</b> Additional supplementation may be required after the initial dose with replenishment occurring over several days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe deficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Manufacturer&rsquo;s labeling: Up to 250 mg/kg within a 4-hour period</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe (&lt;1 mg/dL): 4 to 8 g (up to 0.1875 g/kg), administer at &le;1 g/hour if asymptomatic; in symptomatic patients, may administer &le;4 g over 4-5 minutes (Kraft, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">With polymorphic VT (including torsade de pointes): IV push: 1 to 2 g (ACLS, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Obesity: Weight &gt;130% of ideal body weight (IBW) or body mass index (BMI) &ge;30 kg/m<sup>2</sup>: When determining maximum per kg dose for replacement, some clinicians suggest using adjusted body weight (AdjBW) (Kraft, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AdjBW (men) = ([wt (kg) -IBW (kg)] x 0.3) + IBW</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AdjBW (women) = ([wt (kg) -IBW (kg)] x 0.25) + IBW</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypomagnesemia, prevention (parenteral nutrition supplementation):</b> IV: 8 to 20 mEq elemental magnesium daily (ASPEN [Mirtallo, 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Soaking aid:</b> Topical: Dissolve 2 cupfuls of granules per gallon of warm water; may also soak a towel with the solution to apply as a wet dressing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Asthma (acute severe exacerbations) (off-label use):</b> IV: 2 g as a single dose over 20 minutes (NAEPP, 2007; GINA, 2015); recommended as adjunctive therapy for severe life-threatening exacerbations and for exacerbations that remain severe after 1 hour of intensive conventional therapy (NAEPP, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Torsade de pointes or VF/pulseless VT associated with torsade de pointes (off-label use):</b> IV, I.O.: 1 to 2 g over 15 minutes (ACLS, 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191093\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Magnesium sulfate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dose represented as magnesium sulfate unless stated otherwise. <b>Note:</b> Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b> 1 g of magnesium sulfate = 98.6 mg elemental magnesium = 8.12 mEq elemental magnesium = magnesium 4.06 mmol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Constipation (occasional):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to &lt;12 years: 1 to 2 level teaspoons of granules dissolved in water; may repeat in 4 to 6 hours (maximum: 2 doses/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypomagnesemia, treatment:</b> <b>Note:</b> Treatment depends on severity and clinical status: IV, I.O.: 25 to 50 mg/kg/dose over 10 to 20 minutes (over several minutes for torsade de pointes); maximum single dose: 2000 mg (PALS, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypomagnesemia, prevention (parenteral nutrition supplementation) (ASPEN [Mirtallo, 2004]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;50 kg: 0.3 to 0.5 mEq elemental magnesium/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;50 kg: 10 to 30 mEq elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Asthma (acute severe exacerbations) (off-label use):</b> IV: Children and Adolescents: 25 to 75 mg/kg (maximum: 2000 mg) as a single dose over 20 to 60 minutes (GINA 2015; NAEPP, 2007); recommended as adjunctive therapy for severe life-threatening exacerbations and for exacerbations that remain severe after 1 hour of intensive conventional therapy (NAEPP, 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191086\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191087\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Hypomagnesemia:</i> Renal dysfunction:  Reduce dose by 50% (Kraft, 2005). Use with caution; monitor for hypermagnesemia; Close monitoring is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Pre-eclampsia/eclampsia:</i> Severe renal impairment: Per the manufacturer, do not exceed 20 grams during a 48 hour period. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317811\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20749690\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191066\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Granules, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epsom Salt:  (454 g, 1810 g, 1816 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Epsom Salt:  (1810 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 1 g/50 mL in Dextrose 5% (50 mL); 1 g/50 mL in NaCl 0.9% (50 mL); 10 g/100 mL in Dextrose 5% (100 mL); 10 g/100 mL in NaCl 0.9% (100 mL); 10 g/250 mL in Dextrose 5% (250 mL); 10 g/250 mL in Lactated Ringers (250 mL); 10 g/500 mL (500 mL [DSC]); 2 g/100 mL in Dextrose 5% (100 mL); 2 g/100 mL in NaCl 0.9% (100 mL); 2 g/50 mL (50 mL); 2 g/50 mL in Dextrose 5% (50 mL); 2 g/50 mL in NaCl 0.9% (50 mL); 20 g/250 mL in Lactated Ringers (250 mL); 20 g/500 mL (500 mL); 20 g/500 mL in Dextrose 5% (500 mL); 20 g/500 mL in Lactated Ringers (500 mL); 25 g/250 mL in Lactated Ringers (250 mL); 3 g/50 mL in Dextrose 5% (50 mL); 3 g/50 mL in NaCl 0.9% (50 mL); 4 g/100 mL in Dextrose 5% (100 mL); 4 g/100 mL in NaCl 0.9% (100 mL); 4 g/50 mL (50 mL); 4 g/50 mL in Dextrose 5% (50 mL); 4 g/50 mL in NaCl 0.9% (50 mL); 40 g/1000 mL (1000 mL); 40 g/1000 mL in NaCl 0.9% (1000 mL); 40 g/500 mL in Dextrose 5% (500 mL); 40 g/500 mL in Lactated Ringers (500 mL); 5 g/100 mL in Dextrose 5% (100 mL); 50 g/500 mL in Lactated Ringers (500 mL); 50 mg/500 mL in Dextrose 5% (500 mL); 6 g/100 mL in Dextrose 5% (100 mL); 6 g/150 mL in NaCl 0.9% (150 mL); 6 g/50 mL in Dextrose 5% (50 mL); 6 g/50 mL in NaCl 0.9% (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191050\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963611\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">1 g of magnesium sulfate = elemental magnesium 98.6 mg = magnesium 8.12 mEq = magnesium 4.06 mmol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Magnesium sulfate 1% [10 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.081 mEq/mL. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 2% [20 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.162 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 4% [40 mg/mL] in Water injection is equivalent to elemental magnesium 0.325 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 8% [80 mg/mL] in Water injection is equivalent to elemental magnesium 0.65 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 50% injection is equivalent to elemental magnesium 4 mEq/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191070\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: May be administered IM or IV </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Must be diluted prior to administration for children (Adults: 25% or 50% concentration; Children: &le;20% diluted solution)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Must be diluted to a &le;20% solution for IV infusion and may be administered IV push, IVPB, or continuous IV infusion. When giving IV push, must dilute first and should generally not be given any faster than 150 mg/minute; may administer over 1 to 2 minutes in patients with persistent pulseless VT or VF with known hypomagnesemia (Dager, 2006). ACLS guidelines recommend administration over 15 minutes in patients with torsade de pointes (ACLS, 2010). In patients not in cardiac arrest, hypotension and asystole may occur with rapid administration. In patients with asthma (acute severe exacerbation) (off-label use), may administer single dose over 20 minutes to 60 minutes (GINA 2015; NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximal rate of infusion: Up to 50% of an IV dose may be eliminated in the urine, therefore, slower administration may improve retention (maximum rate: 1 g/hour in asymptomatic patients). For doses &lt;6 g, infuse over 8 to 12 hours and for larger doses infuse over 24 hours if patient is asymptomatic. If patient is severely symptomatic (or has conditions such as preeclampsia or eclampsia) more aggressive therapy (&le;4 g over 4 to 5 minutes) may be required; patients should be closely monitored (Kraft, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: When used as a laxative, dissolve dose in 8 ounces of water prior to ingesting. Lemon juice may be added to the solution to improve the taste. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical: May dissolve granules to prepare a solution for use as a soaking aid or as a compress. To make a compress, use a towel to apply as a wet dressing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191069\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Laxative for the relief of occasional constipation (OTC labeling)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment and prevention of hypomagnesemia; prevention and treatment of seizures in severe pre-eclampsia or eclampsia, pediatric acute nephritis; treatment of cardiac arrhythmias (VT/VF) caused by hypomagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Soaking aid for minor cuts and bruises (OTC labeling)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469380\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Asthma (acute exacerbations); Torsades de pointes or VF/pulseless VT associated with torsades de pointes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191104\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Magnesium sulfate may be confused with manganese sulfate, morphine sulfate </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MgSO<sub>4</sub> is an error-prone abbreviation (mistaken as morphine sulfate) </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191057\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects on neuromuscular function may occur at lower concentrations in patients with neuromuscular disease (eg, myasthenia gravis). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not defined: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (IV; dose related), hypotension (IV; rate related), vasodilation (IV; rate related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypermagnesemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191073\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any component of the formulation; heart block (see <b>Note</b>); myocardial damage; IV use for pre-eclampsia/eclampsia during the 2 hours prior to delivery (see <b>Note</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Although the manufacturers' labeling for some IV formulations state use in pre-eclampsia/eclampsia during the 2 hours prior to (cesarean) delivery is contraindicated due to interaction with neuromuscular-blocking agents intraoperatively; stopping magnesium sulfate prior to cesarean delivery in these patients is not recommended and increases the risk of seizure. Instead, magnesium should be continued prior to and during the delivery (ACOG 2013). Additionally, the manufacturers' labeling for some IV formulations contraindicate the use of magnesium sulfate in the setting of heart block; however, the use of magnesium is appropriate in patients with serious conditions requiring magnesium therapy who either have mild degrees of heart block (eg, first degree) or more severe forms of heart block with a temporary or permanent cardiac pacemaker.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191054\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obstetrics: Vigilant monitoring and safe administration techniques (ISMP, 2005) recommended to avoid potential for errors resulting in toxicity. Monitor mother and fetus closely. Use longer than 5 to 7 days may cause adverse fetal events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Unlikely to effectively terminate irregular/polymorphic VT (with normal baseline QT interval) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte abnormalities:  Concurrent hypokalemia or hypocalcemia can accompany a magnesium deficit. Hypomagnesemia is frequently associated with hypokalemia and requires correction in order to normalize potassium. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral administration: Magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC Use): When used as a soaking aid, patients should not use if there is evidence of infection or prompt relief is not obtained. When used as a laxative, patients should consult a healthcare provider prior to use if they have: kidney disease; are on a magnesium-restricted diet; have abdominal pain, nausea, or vomiting; change in bowel habits lasting &gt;2 weeks; have already used a laxative for &gt;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299640\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9585&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May enhance the adverse/toxic effect of Magnesium Sulfate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4104770\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Increased alcohol intake can deplete magnesium stores (IOM, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191062\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013521\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002). Continuous maternal use for &gt;5 to 7 days (in doses such as those used for preterm labor, an off-label use) may cause fetal hypocalcemia and bone abnormalities, as well as fractures in the neonate. Magnesium sulfate injection is used for the prevention and treatment of seizures in pregnant or postpartum women with severe pre-eclampsia or eclampsia (ACOG 2013; ACOG 652 2016). Magnesium sulfate may also be used prior to early preterm delivery for neuroprotection to reduce the risk of cerebral palsy (ACOG 455 2010; ACOG 652 2016; Reeves 2011); specific regimens are not available, but treatment may be of benefit when birth is anticipated before 32 weeks gestation (ACOG 171 2016; ACOG 172 2016; ACOG 652 2016). Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth; maintenance therapy with tocolytics is ineffective and not recommended. Magnesium sulfate can be used up to 48 hours in women at risk of delivery within 7 days; however, it is not the preferred tocolytic (ACOG 171 2016; ACOG 652 2016). Magnesium sulfate injection may be used in conjunction with other tocolytics for neuroprotection; however, an increased risk of maternal complications may be observed when used in combination with some tocolytic agents (ACOG 171 2016). Magnesium toxicity should be suspected in pregnant women receiving magnesium in respiratory and/or cardiac arrest. Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013524\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997). When magnesium sulfate is used in the intrapartum management of eclampsia, breast milk concentrations are generally increased for only ~24 hours after the end of treatment (Idama, 1998). The manufacturer recommends that caution be used if administered to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191076\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Whole grains, legumes and dark-green leafy vegetables are dietary sources of magnesium (IOM, 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary recommended daily allowance (RDA) (elemental magnesium) (IOM 1997):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: 80 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 8 years: 130 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 13 years: 240 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">14 to 18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 360 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy: 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lactation: 360 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 410 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 30 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 310 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy: 350 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lactation: 310 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;31 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 320 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy: 360 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lactation: 320 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 420 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191064\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium concentrations if frequent or prolonged dosing required particularly in patients with renal dysfunction, calcium, and potassium concentrations; renal function</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obstetrics: Patient status including vital signs, oxygen saturation, deep tendon reflexes, level of consciousness, fetal heart rate, maternal uterine activity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191067\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191053\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">When taken orally, magnesium promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191072\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anticonvulsant: IM: 1 hour; IV: Immediate; Laxative: Oral: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of anticonvulsant activity: IM: 3-4 hours; IV: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Slow and poor (approximately one-third absorbed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%) (IOM 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 30%, to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as magnesium); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323358\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/50 mL 5% (50 mL): $6.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $8.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/50 mL 5% (50 mL): $6.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 5% (100 mL): $6.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/50 mL 5% (50 mL): $7.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/50 mL 5% (50 mL): $7.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/100ML 5% (100 mL): $7.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5GM/100ML 5% (100 mL): $9.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g/50 mL 5% (50 mL): $9.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/100ML 5% (100 mL): $10.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/100ML 5% (100 mL): $13.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/250ML 5% (250 mL): $14.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20GM/500ML 5% (500 mL): $22.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/500ML 5% (500 mL): $40.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50GM/500ML 5% (500 mL): $44.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50% (10 mL): $2.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $17.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/100 mL (100 mL): $8.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 gm/50 mL (50 mL): $8.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/500 mL (500 mL): $6.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/1000ML (1000 mL): $9.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate-Lact Ringers Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/250ML (250 mL): $14.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/500 mL (500 mL): $21.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20GM/250ML (250 mL): $22.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25GM/250ML (250 mL): $25.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/500 mL (500 mL): $36.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/500 mL (500 mL): $42.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/50ML 0.9% (50 mL): $6.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 0.9% (100 mL): $6.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $6.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3GM/50ML 0.9% (50 mL): $8.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/100ML 0.9% (100 mL): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/50ML 0.9% (50 mL): $9.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/100ML 0.9% (100 mL): $9.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/150ML 0.9% (150 mL): $13.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/50ML 0.9% (50 mL): $8.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/100ML 0.9% (100 mL): $12.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/L 0.9% (1000 mL): $41.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4088911\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cholal modificado (MX);</li>\n      <li>Inj. Magnesii Sulfurici (PL);</li>\n      <li>Kiddi Pharmaton (MX);</li>\n      <li>Magnesii Sulfas (PL);</li>\n      <li>Magnesii Sulfas Siccatus (PL);</li>\n      <li>Magnesium Sulfuricum (PL);</li>\n      <li>Magunesin (KR);</li>\n      <li>Vivioptal Junior (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Task Force Report on Hypertension in Pregnancy. http://www.acog.org/Resources_And_Publications/Task_Force_and_Work_Group_Reports/Hypertension_in_Pregnancy. Updated 2013. Accessed February 3, 2014.16175681</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27661654\"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi: 10.1097/AOG.0000000000001711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/27661654/pubmed\" target=\"_blank\" id=\"27661654\">27661654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College Of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 172: Premature Rupture of Membranes. <i>Obstet Gynecol</i>. 2016;128(4):e165-e177. doi: 10.1097/AOG.0000000000001712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/26695586/pubmed\" target=\"_blank\" id=\"26695586\">26695586</a>]</span><span class=\"doi\">10.1097/AOG.0000000000001712</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;Committee Opinion No. 455: Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection,&quot; <i>Obstet Gynecol</i>, 2010, 115(3):669-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/20177305/pubmed\" target=\"_blank\" id=\"20177305\">20177305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 652: Magnesium Sulfate Use in Obstetrics. <i>Obstet Gynecol</i>. 2016;127(1):e52-e53. doi: 10.1097/AOG.0000000000001267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/26695587/pubmed\" target=\"_blank\" id=\"26695587\">26695587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo; <i>Muscle Nerve</i>, 1990, 13(8):708-12.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bohman VR and Cotton DB, &ldquo;Supralethal Magnesemia With Patient Survival,&rdquo; <i>Obstet Gynecol</i>, 1990, 76(5 Pt 2):984-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catanzarite VA, McHargue AM, Sandberg EC, et al, &ldquo;Respiratory Arrest During Therapy for Premature Labor in a Patient With Myasthenia Gravis,&rdquo; <i>Obstet Gynecol</i>, 1984, 64(6):819-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo; <i>Crit Care Med</i>, 1982, 10(3):193-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen BA, London RS, and Goldstein PJ, &ldquo;Myasthenia Gravis and Preeclampsia,&rdquo; <i>Obstet Gynecol</i>, 1976, 48(1 Suppl):35-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(12):1703-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/17125434/pubmed\" target=\"_blank\" id=\"17125434\">17125434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dube L and Granry JC, &ldquo;The Therapeutic Use Of Magnesium In Anesthesiology, Intensive Care And Emergency Medicine: A Review,&rdquo; <i>Can J Anaesth</i>, 2003, 50(7):732-46.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferroggiaro A, Walther JM, and Cairns CB, &ldquo;High Doses of Magnesium Impair Cardiac Oxidative Metabolism,&rdquo; <i>Acad Emerg Med</i>, 1995, 2:423-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/documents/4. Updated April 2015. Accessed June 22, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gums JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(3):240-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gums JG, &ldquo;Magnesium in Cardiovascular and Other Disorders,&rdquo; <i>Am J Health Sys Pharm</i>, 2004, 61(15): 1569-76.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idama TO and Lindow SW, &ldquo;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&rdquo; <i>Br J Obstet Gynaecol</i>, 1998, 105(3):260-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP), &ldquo;Preventing Magnesium Toxicity in Obstetrics,&rdquo; ISMP Acute Care Medication Safety Alert, October 20, 2005. Available online at http://www.ismp.org/Newsletters/acutecare/articles/20051020.asp.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, National Academy of Sciences, Washington, DC, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaeser HE, &ldquo;Drug-Induced Myasthenia Gravis,&rdquo; <i>Acta Neurol Scand Suppl</i>, 1984, 100:39-47.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support (PALS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft MD, Btaiche IF, Sacks GS, et al,  &ldquo;Treatment of Electrolyte Disorders in Adult Patients in the Intensive Care Unit,&rdquo; <i>Am J Health-Syst Pharm</i>, 2005, 62(16):1663-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/16085929/pubmed\" target=\"_blank\" id=\"16085929\">16085929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas MJ, Leveno KJ, and Cunningham FG, &ldquo;A Comparison of Magnesium Sulfate With Phenytoin for the Prevention of Eclampsia,&rdquo; <i>N Engl J Med</i>, 1995, 333(4):201-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):39-70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support (ACLS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osada H, Watanabe Y, Nishimura Y, et al, &quot;Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,&quot; <i>Acta Obstet Gynecol Scand</i>, 2002, 81(10):931-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/12366483/pubmed\" target=\"_blank\" id=\"12366483\">12366483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeves SA, Gibbs RS, and Clark SL, &quot;Magnesium for Fetal Neuroprotection,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(3):202.1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/21376159/pubmed\" target=\"_blank\" id=\"21376159\">21376159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vissers R and Purssell R, &ldquo;Iatrogenic Intravenous Magnesium Overdose Causing Cardiac Arrest,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1995, 33(5):489.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Worthley LI, &ldquo;Lithium Toxicity and Refractory Cardiac Arrhythmia Treated With Intravenous Magnesium,&rdquo; <i>Anaesth Intensive Care</i>, 1974, 2(4):357-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-drug-information/abstract-text/4447250/pubmed\" target=\"_blank\" id=\"4447250\">4447250</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9585 Version 197.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452590\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F191096\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F191085\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F191093\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F191086\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F191087\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16317811\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20749690\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F191066\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F191050\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963611\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F191070\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F191069\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469380\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F191104\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F191057\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F191073\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F191054\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299640\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F191059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F4104770\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F191062\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3013521\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3013524\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F191076\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F191064\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F191067\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F191053\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F191072\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323358\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4088911\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9585|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=magnesium-sulfate-patient-drug-information\" class=\"drug drug_patient\">Magnesium sulfate: Patient drug information</a></li><li><a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium sulfate: Pediatric drug information</a></li></ul></div></div>","javascript":null}